{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:25:44Z","timestamp":1791404744877,"version":"4.3.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T00:00:00Z","timestamp":1284336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T00:00:00Z","timestamp":1284336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2011,1,13]]},"DOI":"10.1038\/onc.2010.409","type":"journal-article","created":{"date-parts":[[2010,9,13]],"date-time":"2010-09-13T13:02:44Z","timestamp":1284382964000},"page":"223-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["BCR\u2013ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients"],"prefix":"10.1038","volume":"30","author":[{"given":"D D","family":"De Carvalho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Binato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W O","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M G","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M D","family":"Colassanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Proto-Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A E B","family":"Bueno-Da-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Zago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Zanichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Abdelhay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F A","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"Jacysyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G P","family":"Amarante-Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,13]]},"reference":[{"key":"BFonc2010409_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/89050","volume":"7","author":"L Altucci","year":"2001","unstructured":"Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H . (2001). Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 7: 680\u2013686.","journal-title":"Nat Med"},{"key":"BFonc2010409_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/sj.cdd.4400276","volume":"4","author":"GP Amarante-Mendes","year":"1997","unstructured":"Amarante-Mendes GP, Jascur T, Nishioka WK, Mustelin T, Green DR . (1997). Bcr\u2014Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity. Cell Death Differ 4: 548\u2013554.","journal-title":"Cell Death Differ"},{"key":"BFonc2010409_CR3","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","volume":"91","author":"GP Amarante-Mendes","year":"1998","unstructured":"Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR et al. (1998). Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91: 1700\u20131705.","journal-title":"Blood"},{"key":"BFonc2010409_CR4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","volume":"83","author":"A Bedi","year":"1994","unstructured":"Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ . (1994). Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83: 2038\u20132044.","journal-title":"Blood"},{"key":"BFonc2010409_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/nm733","volume":"8","author":"DG Beer","year":"2002","unstructured":"Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE et al. (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816\u2013824.","journal-title":"Nat Med"},{"key":"BFonc2010409_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0014-5793(03)00299-0","volume":"541","author":"G Brumatti","year":"2003","unstructured":"Brumatti G, Weinlich R, Chehab CF, Yon M, Amarante-Mendes GP . (2003). Comparison of the anti-apoptotic effects of Bcr-Abl, Bcl-2 and Bcl-x(L) following diverse apoptogenic stimuli. FEBS Lett 541: 57\u201363.","journal-title":"FEBS Lett"},{"key":"BFonc2010409_CR7","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/sj.cdd.4401210","volume":"10","author":"AE Bueno-da-Silva","year":"2003","unstructured":"Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP . (2003). Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ 10: 592\u2013598.","journal-title":"Cell Death Differ"},{"key":"BFonc2010409_CR8","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1038\/sj.emboj.7600302","volume":"23","author":"N Clarke","year":"2004","unstructured":"Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H . (2004). Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 23: 3051\u20133060.","journal-title":"EMBO J"},{"key":"BFonc2010409_CR9","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.4049\/jimmunol.168.3.1356","volume":"168","author":"E Cretney","year":"2002","unstructured":"Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ . (2002). Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356\u20131361.","journal-title":"J Immunol"},{"key":"BFonc2010409_CR10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/sj.cr.7290311","volume":"15","author":"RA Daniels","year":"2005","unstructured":"Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch\u2032En P et al. (2005). Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 15: 430\u2013438.","journal-title":"Cell Res"},{"key":"BFonc2010409_CR11","doi-asserted-by":"publisher","first-page":"10639","DOI":"10.1158\/0008-5472.CAN-06-2522","volume":"66","author":"MT Epping","year":"2006","unstructured":"Epping MT, Bernards R . (2006). A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 66: 10639\u201310642.","journal-title":"Cancer Res"},{"key":"BFonc2010409_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R . (2005). The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122: 835\u2013847.","journal-title":"Cell"},{"key":"BFonc2010409_CR13","doi-asserted-by":"publisher","first-page":"17777","DOI":"10.1073\/pnas.0702518104","volume":"104","author":"MT Epping","year":"2007","unstructured":"Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R et al. (2007). A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA 104: 17777\u201317782.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010409_CR14","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.1073\/pnas.0501564102","volume":"102","author":"C Haqq","year":"2005","unstructured":"Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL et al. (2005). The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102: 6092\u20136097.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010409_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","volume":"19","author":"KS Hoek","year":"2006","unstructured":"Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 19: 290\u2013302.","journal-title":"Pigment Cell Res"},{"key":"BFonc2010409_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C et al. (1997). Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6: 199\u2013208.","journal-title":"Immunity"},{"key":"BFonc2010409_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm1160","volume":"11","author":"A Insinga","year":"2005","unstructured":"Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. (2005). Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71\u201376.","journal-title":"Nat Med"},{"key":"BFonc2010409_CR18","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1111\/j.1349-7006.2007.00623.x","volume":"98","author":"S Kikuchi","year":"2007","unstructured":"Kikuchi S, Nagai T, Kunitama M, Kirito K, Ozawa K, Komatsu N . (2007). Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci 98: 1949\u20131958.","journal-title":"Cancer Sci"},{"key":"BFonc2010409_CR19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1056\/NEJM198810133191506","volume":"319","author":"R Kurzrock","year":"1988","unstructured":"Kurzrock R, Gutterman JU, Talpaz M . (1988). The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319: 990\u2013998.","journal-title":"N Engl J Med"},{"key":"BFonc2010409_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/sj.cdd.4400213","volume":"4","author":"AJ McGahon","year":"1997","unstructured":"McGahon AJ, Brown DG, Martin SJ, Amarante-Mendes GP, Cotter TG, Cohen GM et al. (1997). Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: characterization of the apoptotic death. Cell Death Differ 4: 95\u2013104.","journal-title":"Cell Death Differ"},{"key":"BFonc2010409_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ . (2007). Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7: 441\u2013453.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2010409_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nm1161","volume":"11","author":"A Nebbioso","year":"2005","unstructured":"Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P et al. (2005). Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 11: 77\u201384.","journal-title":"Nat Med"},{"key":"BFonc2010409_CR23","first-page":"350","volume":"7","author":"R Nimmanapalli","year":"2001","unstructured":"Nimmanapalli R, Porosnicu M, Nguyen D, Worthington E, O\u2032Bryan E, Perkins C et al. (2001). Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 7: 350\u2013357.","journal-title":"Clin Cancer Res"},{"key":"BFonc2010409_CR24","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","volume":"10","author":"A Oberthuer","year":"2004","unstructured":"Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M . (2004). The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 10: 4307\u20134313.","journal-title":"Clin Cancer Res"},{"key":"BFonc2010409_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.pai.0000157905.30872.9f","volume":"14","author":"NK Popnikolov","year":"2006","unstructured":"Popnikolov NK, Gatalica Z, Adegboyega PA, Norris BA, Pasricha PJ . (2006). Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)\/Apo2L in Barrett\u2032s esophagus with dysplasia and adenocarcinoma. Appl Immunohistochem Mol Morphol 14: 161\u2013165.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"BFonc2010409_CR26","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.leukres.2006.02.031","volume":"30","author":"R Proto-Siqueira","year":"2006","unstructured":"Proto-Siqueira R, Figueiredo-Pontes LL, Panepucci RA, Garcia AB, Rizzatti EG, Nascimento FM et al. (2006). PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res 30: 1333\u20131339.","journal-title":"Leuk Res"},{"key":"BFonc2010409_CR27","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. (2006). Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 103: 2794\u20132799.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2010409_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1476-5586(04)80047-2","volume":"6","author":"DR Rhodes","year":"2004","unstructured":"Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1\u20136.","journal-title":"Neoplasia"},{"key":"BFonc2010409_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ccr.2006.01.013","volume":"9","author":"AL Richardson","year":"2006","unstructured":"Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A et al. (2006). X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121\u2013132.","journal-title":"Cancer Cell"},{"key":"BFonc2010409_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0950-3536(97)80004-2","volume":"10","author":"CL Sawyers","year":"1997","unstructured":"Sawyers CL . (1997). Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol 10: 223\u2013231.","journal-title":"Baillieres Clin Haematol"},{"key":"BFonc2010409_CR31","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . (1999). Chronic myeloid leukemia. N Engl J Med 340: 1330\u20131340.","journal-title":"N Engl J Med"},{"key":"BFonc2010409_CR32","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/nm1202-797","volume":"8","author":"C Schmaltz","year":"2002","unstructured":"Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA, Ongchin J et al. (2002). T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8: 1433\u20131437.","journal-title":"Nat Med"},{"key":"BFonc2010409_CR33","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6","volume":"32","author":"LM Sedger","year":"2002","unstructured":"Sedger LM, Glaccum MB, Schuh JC, Kanaly ST, Williamson E, Kayagaki N et al. (2002). Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL\/Apo2L, using TRAIL\/Apo2L gene-deficient mice. Eur J Immunol 32: 2246\u20132254.","journal-title":"Eur J Immunol"},{"key":"BFonc2010409_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0014-4827(03)00350-1","volume":"290","author":"EM Souza-Fagundes","year":"2003","unstructured":"Souza-Fagundes EM, Brumatti G, Martins-Filho OA, Correa-Oliveira R, Zani CL, Amarante-Mendes GP . (2003). Myriadenolide, a labdane diterpene isolated from Alomia myriadenia (asteraceae) induces depolarization of mitochondrial membranes and apoptosis associated with activation of caspases-8, -9, and -3 in Jurkat and THP-1 cells. Exp Cell Res 290: 420\u2013426.","journal-title":"Exp Cell Res"},{"key":"BFonc2010409_CR35","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/S0002-9440(10)61257-6","volume":"167","author":"RS Stearman","year":"2005","unstructured":"Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn Jr PA et al. (2005). Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167: 1763\u20131775.","journal-title":"Am J Pathol"},{"key":"BFonc2010409_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cancergencyto.2007.05.011","volume":"177","author":"D Steinbach","year":"2007","unstructured":"Steinbach D, Pfaffendorf N, Wittig S, Gruhn B . (2007). PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia. Cancer Genet Cytogenet 177: 51\u201354.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFonc2010409_CR37","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/10428190802035933","volume":"49","author":"N Tajeddine","year":"2008","unstructured":"Tajeddine N, Louis M, Vermylen C, Gala JL, Tombal B, Gailly P . (2008). Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo. Leuk Lymphoma 49: 1123\u20131131.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2010409_CR38","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1084\/jem.20011171","volume":"195","author":"K Takeda","year":"2002","unstructured":"Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H et al. (2002). Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195: 161\u2013169.","journal-title":"J Exp Med"},{"key":"BFonc2010409_CR39","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1006\/cimm.2001.1896","volume":"214","author":"K Takeda","year":"2001","unstructured":"Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Yamaguchi N, Yagita H et al. (2001). Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol 214: 194\u2013200.","journal-title":"Cell Immunol"},{"key":"BFonc2010409_CR40","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1084\/jem.20031457","volume":"199","author":"K Takeda","year":"2004","unstructured":"Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE et al. (2004). Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199: 437\u2013448.","journal-title":"J Exp Med"},{"key":"BFonc2010409_CR41","first-page":"99","volume":"287","author":"D Umlauf","year":"2004","unstructured":"Umlauf D, Goto Y, Feil R . (2004). Site-specific analysis of histone methylation and acetylation. Methods Mol Biol 287: 99\u2013120.","journal-title":"Methods Mol Biol"},{"key":"BFonc2010409_CR42","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2002-06-1770","volume":"101","author":"K Uno","year":"2003","unstructured":"Uno K, Inukai T, Kayagaki N, Goi K, Sato H, Nemoto A et al. (2003). TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 101: 3658\u20133667.","journal-title":"Blood"},{"key":"BFonc2010409_CR43","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van\u2032t Veer","year":"2002","unstructured":"van\u2032t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530\u2013536.","journal-title":"Nature"},{"key":"BFonc2010409_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1471-2407-7-108","volume":"7","author":"N Vigneswaran","year":"2007","unstructured":"Vigneswaran N, Baucum DC, Wu J, Lou Y, Bouquot J, Muller S et al. (2007). Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer 7: 108.","journal-title":"BMC Cancer"},{"key":"BFonc2010409_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. (1999). Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157\u2013163.","journal-title":"Nat Med"},{"key":"BFonc2010409_CR46","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS . (2003). TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22: 8628\u20138633.","journal-title":"Oncogene"},{"key":"BFonc2010409_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0014-5793(00)01112-1","volume":"466","author":"K Watari","year":"2000","unstructured":"Watari K, Tojo A, Nagamura-Inoue T, Nagamura F, Takeshita A, Fukushima T et al. (2000). Identification of a melanoma antigen, PRAME, as a BCR\/ABL-inducible gene. FEBS Lett 466: 367\u2013371.","journal-title":"FEBS Lett"},{"key":"BFonc2010409_CR48","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673\u2013682.","journal-title":"Immunity"},{"key":"BFonc2010409_CR49","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2008.161","volume":"22","author":"AS Yong","year":"2008","unstructured":"Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM et al. (2008). Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 22: 1721\u20131727.","journal-title":"Leukemia"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2010409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010409","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2010409.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:28:43Z","timestamp":1647883723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2010409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,13]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1,13]]}},"alternative-id":["BFonc2010409"],"URL":"https:\/\/doi.org\/10.1038\/onc.2010.409","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,13]]},"assertion":[{"value":"15 March 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}